According to GlobalData, Phase II drugs for Androgen-Sensitive Prostate Cancer does not have ... a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung ...

“Our study revealed that approximately 30% to 35% of nearly 16,000 men in the United Kingdom with high-risk localized or locally advanced prostate cancer did not receive potentially curative ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Penile Cancer.

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer ... active surveillance for ...

Sir Chris Hoy hailed the fundraising as a “huge step forward” in the fight to make change. "The huge sum Paddy Power are ...

EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first ...

Although prostate cancer screening has been embraced by ... treatment over antiandrogen monotherapy in the setting of locally advanced disease. This study reveals the importance of radiation ...

National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced the creation of a new Theranostics ...

This study aims to report the oncological, surgical and functional outcomes in 15 patients with locally advanced penile cancer who underwent total penile ... were assessed by the International ...

Cilag’s Rybrevant in combo with Lazcluze for first-line treatment of patients with EGFR-mutated advanced NSCLC: Beerse, Belgium Tuesday, Dec ...